We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

104 hedge funds and large institutions have $249M invested in Progenics Pharmaceuticals Inc in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $262M → $249M (-$12.8M)

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

13% less funds holding

Funds holding: 120 → 104 (-16)

52% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 29

86% less call options, than puts

Call options by funds: $334K | Put options by funds: $2.47M

Holders
104
Holders Change
-16
Holders Change %
-13.33%
% of All Funds
2.77%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
31
Reduced
33
Closed
29
Calls
$334K
Puts
$2.47M
Net Calls
-$2.14M
Net Calls Change
-$2.04M

Top Buyers

Rank Fund Capital Flow
1
PA
Pinnacle Associates
New York
+$13.7M
2
AAP
Ardsley Advisory Partners
Connecticut
+$1.93M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.16M
4
ACP
Acuta Capital Partners
California
+$1.04M
5
Deutsche Bank
Deutsche Bank
Germany
+$617K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.51M
2
Millennium Management
Millennium Management
New York
-$1.9M
3
BBA
Baker Bros. Advisors
New York
-$1.84M
4
GCP
GSA Capital Partners
United Kingdom
-$1.81M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
CHAM
51
Clear Harbor Asset Management
Connecticut
$237K -$2.61K -540 -1%
Manulife (Manufacturers Life Insurance)
52
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$221K +$24.7K +5,118 +11%
Goldman Sachs
53
Goldman Sachs
New York
$215K +$146K +30,299 +147%
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
$212K – – –
HCM
55
Hollencrest Capital Management
California
$211K – – –
State Board of Administration of Florida Retirement System
56
State Board of Administration of Florida Retirement System
Florida
$191K – – –
NFA
57
Nationwide Fund Advisors
Ohio
$187K – – –
VKH
58
Virtu KCG Holdings
New York
$184K +$87.6K +18,142 +71%
UBS Group
59
UBS Group
Switzerland
$178K +$124K +25,596 +155%
AIG
60
American International Group
New York
$169K -$3.47K -718 -2%
Ameriprise
61
Ameriprise
Minnesota
$156K -$2.91K -602 -2%
UBS AM
62
UBS AM
Illinois
$144K – – –
PAM
63
Panagora Asset Management
Massachusetts
$139K – – –
CAM
64
CG Asset Management
New York
$137K -$33.8K -7,000 -18%
SO
65
STRS Ohio
Ohio
$136K -$364K -75,300 -70%
Axa
66
Axa
France
$135K +$71.5K +14,800 +87%
VOYA Investment Management
67
VOYA Investment Management
Georgia
$134K – – –
GI
68
GAMCO Investors
Connecticut
$106K +$121K +25,000 New
Balyasny Asset Management
69
Balyasny Asset Management
Illinois
$103K +$13.1K +2,706 +12%
BG
70
BlackRock Group
United Kingdom
$102K -$1.9K -394 -2%
Morgan Stanley
71
Morgan Stanley
New York
$100K +$22K +4,563 +24%
PAM
72
Princeton Alpha Management
New Jersey
$100K +$115K +23,774 New
Stifel Financial
73
Stifel Financial
Missouri
$99K +$113K +23,451 New
FP
74
Foundry Partners
Minnesota
$75K – – –
Bank of America
75
Bank of America
North Carolina
$73K +$49K +10,138 +145%
1 2
3
4 5

PGNX Hedge Fund Activity: Q2 2016 in Review

104 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2016, worth a combined $249M — down 4.9% from $262M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of PGNX and 14 opened new positions — a net loss of 15 holders — while 33 trimmed existing stakes and 31 added.

The largest buyer was Pinnacle Associates, opening a new position worth an estimated $13.7M. The largest seller was Fidelity Investments, cutting an estimated $4.51M.

  • 104 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2016, down from 120 in Q1 2016.
  • Funds reported $249M of Progenics Pharmaceuticals Inc stock for Q2 2016, down 4.9% quarter-over-quarter.
  • 14 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2016 and 29 closed out, a net change of -15 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2016 was Pinnacle Associates, an estimated $13.7M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2016 was Fidelity Investments, an estimated $4.51M sold.

Based on aggregated 13F filings for Q2 2016.